In 2020, the Darnytsia company produced 10 new drug brands used in cardiology, neurology, and other therapeutic areas. The company invested 24% of its gross profit in the development of these drugs. This was reported by the head of the Board of Directors of the Darnytsia Group, Dmytro Shymkiv.
He also added that Darnytsia closed joint-stock company is a recognized leader of the Ukrainian pharmaceutical industry. The company considers its mission to provide patients with effective and affordable medicines. In the context of its implementation, from 2015 to 2019, the pharmaceutical concern released more than 40 brands by investing about UAH 1 billion in their development. According to Dmytro Shymkiv, in order to meet the constantly growing market needs and quickly respond to new challenges, in 2020, the company switched to a flexible schedule of production planning. By keeping this objective, the concern orchestrated the work on ensuring and maintaining a strategic stock of pharmaceutical substances. Moreover, the Darnitsa Group management took care of their employees’ health by introducing new rules dictated by the coronavirus pandemic.
While announcing the list of new brands, Dmytro Shymkiv named such over-the-counter (OTC) drugs as herbal mucolytic Ritosse® Plantain and the sedative sleeping pills Hypnosis®. The list of new prescription drugs produced by Darnytsia includes Efstat® for treating gout and suppression of the function of uric acid production, Alfackholin®, used for cognitive disorders of the central nervous system, a unique injectable combined anesthetic drug Neopastil, a drug for treating arterial hypertension and prevention myocardial infarction Tiara Solo®, and also a pharmaceutical agent for increasing mental performance and normalizing sleep Glitsyn-Darnytsia®. The top manager singled out separately a broad-spectrum antiseptic Darsept®. It does not belong to the drug category but is manufactured in accordance with high standards.
Dmytro Shymkiv specified that the Darnytsia production strategy remains unchanged, despite the global challenges faced by both the domestic and international pharmaceutical industry. It consists of providing effective treatment for diseases of the cardiovascular and nervous systems and combating pain.